Anneli Savinainen

Anneli Savinainen has extensive experience in preclinical development and R&D in the pharmaceutical industry. Anneli is currently serving as the Vice President and Head of Preclinical Development at Mariana Oncology since March 2023. Previously, they held the positions of Vice President and Head of Preclinical R&D at Aura Biosciences from April 2022 to March 2023 and Senior Director and Head of Preclinical R&D from July 2019 to April 2022. Anneli has also worked as the Director of Preclinical Pharmacology and Toxicology at Syros Pharmaceuticals from August 2018 to July 2019. Before that, they held leadership roles at Shire, including Director of Pharmacology in Global Nonclinical Development from March 2018 to August 2018 and Associate Director of Pharmacology in Global Nonclinical Development from July 2015 to March 2018. Anneli's earlier experiences include roles at EMD Serono, Inc., Resolvyx Pharmaceuticals, MILLENNIUM PHARMACEUTICALS, INC, and AstraZeneca, where they gained comprehensive knowledge in translational research, in-vivo pharmacology, and gastrointestinal pharmacology.

Anneli Savinainen obtained a Master Certificate in Clinical Trial and Project Management from Northeastern University in 2004-2005. Prior to that, they pursued a Master's degree in Pharmacology at Northeastern University from 1999-2001. In 2001, they also completed a course on Pharmacokinetics and Toxicokinetics for the Industrial Scientist at the University of Arizona. Additionally, Anneli attended Harvard University from 2001-2005, although the specific degree and field of study are unknown. There is no information available about their education at the University of California.